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Path-breaking innovations for lung 
cancer: a revolution in clinical practice 
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CNR - National Research Council of Italy 
& GEORGIA INSTITUTE OF TECHNOLOGY 
 
ABSTRACT:  Lung cancer is one of main cause of death worldwide and traditional 
chemotherapy agents have reached the maturity phase in the treatment of advanced non-small 
cell lung cancer. The purpose of this paper is to analyse the evolutionary growth of knowledge 
patterns of vital radical innovations to treat lung cancer, driven by new technological paradigm 
of the targeted therapy, that have generating a revolution in clinical practice, increasing the 
overall survival of patients and quality of life. This new scientific pathway has evolving with an 
allometric process that involves a disproportionate growth of targeted therapy in relation to 
standard platinum-based chemotherapy alone.  
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La  scienza di oggi è la vita di domani 
(Science of today is life of tomorrow) 
Università degli Studi di Macerata, Italy 
 
1. INTRODUCTION 
esearch and experimental 
Development (R&D) processes 
consume considerable economic 
and human resources and 
contribute to the accumulation of intangible 
capital, which is fostering drug discoveries 
and medical innovations that lead to longer, 
better and healthier living. R&D intensity is 
higher in economic systems driven mainly by 
pharmaceuticals, chemicals industry, ICTs 
because it represents the main determinant of 
scientific and technological advances (Van 
Pottelsberghe de la Potterie, 2008, pp. 222-
224). In fact, Mathieu and Van Pottelsberghe 
de la Potterie (2008) show that R&D intensity 
of Drug & Medicines industry (average across 
10 countries in %) has high levels of about 
20%. The R&D of this vital industry has 
supporting the convergence of genetics1 and 
genomics2 that has originating new pathways 
of anticancer drugs (Amir-Aslani and 
Mangematin, 2010). In particular, the 
interaction between medicinal chemistry and 
genomics has created the pharmacogenomics 
that examines the way drugs act on cells as 
revealed by their gene expression patterns. 
Lindpaintner (1999) argues that these 
breakthroughs are the basis for the 
development of personalized medicines (e.g. 
targeted therapy). The genomics has providing 
opportunities for new treatments in more than 
100 multifactoral diseases, with 500-1000 
disease-related genes and 3000-10,000 new 
drug targets (Jain, 2000, p. 318). Genetics, 
instead, has playing a key role because several 
tumors have a genetic component and 
                                                                    
1 Genetics studies the molecular structure and 
function of genes in the context of a cell or 
organism. 
2 Genomics is a discipline in genetics that studies 
the genomes of organisms. In particular, it 
determines the entire DNA sequence of 
organisms and fine-scale genetic mapping 
efforts. 
scientific advances in this critical scientific 
field, associated to proteomics3, have helping 
to understand the disease biology in order to 
support effective new anticancer drugs for 
modern clinical practice (Jain, 2000, p. 319). 
A main illness across several countries is 
the lung cancer that is a leading cause of 
cancer death worldwide (Laack et al., 2010, p. 
259). In particular, 85% of cases are 
represented by Non-Small Cell Lung Cancer 
(NSCLC), which is due to risk factors such as 
smoking, passive smoking and air pollution 
(cf. Molina et al., 2008, passim). The 
treatments of advanced Non-Small Cell Lung 
Cancer (NSCLC), based on traditional 
chemotherapy agents, have reached the 
maturity phase and the current progress in 
genetics, genomics and proteomics represents 
the vast foundation underlying the recently 
development of new anticancer drugs for 
targeted therapy (Mitsudomi, 2010, p. 101). 
The purpose of this paper is to analyze the 
current scientific and technological pathway 
of vital radical innovations applied as targeted 
therapy to treat NSCLC that has generating a 
revolution in clinical practice. This important 
topic, based on evolutionary growth of 
knowledge of some new targeted therapies, 
can shed light on the common origin and 
evolution of several new drugs that has 
driving the modern medicine. Before 
analyzing the ongoing evolutionary pathways 
of radical innovations for lung cancer, next 
section describes the interesting history of 
these new anticancer drugs. 
2. FROM ADVANCES IN 
MOLECULAR BIOLOGY TO TARGETED 
THERAPY: THE HISTORICAL ASPECTS 
OF VITAL RADICAL INNOVATIONS FOR 
LUNG CANCER 
Cancer is an organism which lives off a host 
organ, growing by bio-genetic-molecular 
mechanism.  
Lung cancer is a: “Cancer that forms in 
tissues of the lung, usually in the cells lining 
air passages.” (as defined by National Cancer 
Institute, 2011). Mitsudomi (2010, p. 101) 
                                                                    
3 The proteomics is the systematic analysis of 
protein profiles of tissues and parallels the 
related field of genomics.  
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claims that: “lung cancer is a major cause of 
cancer-related mortality worldwide”. In fact, 
Table 1 shows as lung cancer has the highest 
mortality rate (24.8) across developed regions 
(cf. also Parkin et al., 2005). The 
Surveillance, Epidemiology and End Results 
(SEER) Program for cancer statistics in the 
United States estimates that 222,520 men and 
women (116,750 men and 105,770 women) 
 
are diagnosed with and 157,300 men and 
women are died of cancer of the lung and 
bronchus in 2010 (SEER, 2011). The median 
age at diagnosis for cancer of the lung and 
bronchus is about 71 years. Based on rates 
from 2005-2007, 6.95% of men and women 
born today will be diagnosed with cancer of 
the lung and bronchus at some time during 
their lifetime (Howlader et al., 2011).  
 
 
Table 1. Most frequent cancers in developed regions (both sexes) 
Cancer Incidence Mortality 
 ASR (W)* ASR (W)* 
 Lung 31.3 24.8 
 Breast 66.4 15.3 
 Colorectum 30.1 12 
 Prostate 61.7 10.5 
 Stomach 11.4 7.2 
 Pancreas 6.8 6.4 
 Ovary 9.3 5.1 
 Liver 5.2 4.6 
 Leukaemia 7.3 3.7 
 Cervix uteri 9.1 3.2 
 Brain, nervous system 5.1 3.2 
 Oesophagus 3.6 2.9 
 Kidney 8.6 2.8 
 Non-Hodgkin lymphoma 8.6 2.8 
 Bladder 9.1 2.5 
 Corpus uteri 13 2.3 
 Gallbladder 2.2 1.5 
 Multiple myeloma 2.7 1.5 
Lip, oral cavity 4.4 1.4 
 Melanoma of skin 9 1.4 
 Other pharynx 2.5 1.2 
 Larynx 2.8 1.2 
 Thyroid 6.1 0.4 
 Testis 4.6 0.3 
 Hodgkin lymphoma 2 0.3 
Note: Incidence and Mortality: Population weighted average of the country rates applied to the 
2008 area population. Age-Standardised Rate-ASR (W): A rate is the number of new cases or 
deaths per 100 000 persons per year. An age-standardised rate is the rate that a population 
would have if it had a standard age structure.  
Source International Agency for research on cancer. World Health Organization. 
GLOBOCAN 2008 (IARC) Section of Cancer Information (5/7/2011).http://globocan.iarc.fr/ 
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Figure 1: Convergence of scientific fields driving drug discovery pathway 
 
The two main typologies of lung cancer are: 
small cell lung cancer and non-small cell lung 
cancer (NSCLC), which represents about 80% 
of cases. The stage of the illness is essential to 
treat the patients with lung cancer. Surgical 
resection is the most apt medical strategy of 
treatment when the disease is at the early 
stage.  
However, about 70% of patients with lung 
cancer have micro (i.e. locally: in contiguous 
lobes) and macro metastases (spread in the 
next lung, brain and/or bones) when 
diagnosed (Laack et al., 2010, p. 259; cf. also 
Molina et al., 2008). The five-year survival 
rate of these patients is about 2-10% with 
current treatments based on chemotherapy 
agents (see Reck and Crinò, 2009, p. 1). 
Up-to-date Cisplatin based therapy is the 
reference treatment for advanced NSCLC, but 
these traditional chemotherapy agents have 
reached a therapeutic maturity since the 
convergence of vital research fields, 
represented in figure 1 (grey area), has 
generated the insurgence of new technological 
paradigms that branch off technological 
trajectories of revolutionary anticancer drugs 
with higher effectiveness to treat cancers and 
lower adverse drug reactions. In particular, 
scientific advances in genomics, genetics and 
proteomics (fig. 1) have paved the pathway to 
potential technological paradigms that the 
“focusing devices” (Sahal, 1981) select on the 
basis of ex-ante and ex-post elements and give  
rise to some technological paradigms4 (Dosi, 
1982) represented by (Figure 2):  
                                                                    
4 “ „model‟ and „pattern‟ of solution of selected 
technological problems, based on selected 
principles derived from the natural science and 
a) Gene therapy is an experimental 
treatment that involves introducing genetic 
material (DNA or RNA) into a person's cells 
to fight disease;  
b) biological therapies use the body's 
immune system, either directly or indirectly, 
to fight cancer or to lessen the side effects that 
may be caused by some cancer treatments;  
c) cancer vaccines boost the immune 
system‟s natural ability to protect the body 
against infectious agents, that may cause 
disease;  
d) Targeted cancer therapies: “are drugs or 
other substances that block the growth and 
spread of cancer by interfering with specific 
molecules involved in tumor growth and 
progression” (as defined by National Cancer 
Institute, 2011).Gene and biological therapies 
as well as cancer vaccines are often 
considered to be targeted therapies.  
The technological paradigm of targeted cancer 
therapies has spreading technological 
trajectories based on radical and incremental 
innovations and the main typologies are: 
signal transduction inhibitors, therapies that 
modify the function of proteins regulating 
gene expression and other cellular functions, 
targeted therapies inducing cancer cells to 
undergo apoptosis (cell death), other targeted 
therapies block the growth of blood vessels to 
tumors, some targeted therapies also act by 
supporting the immune system to destroy 
cancer cells and a class of targeted therapies 
includes monoclonal antibodies that deliver 
toxic molecules to cancer cells specifically 
(cf. National Cancer Institute, 2011, passim). 
                                                                                                
on selected material technologies” (Dosi, 1982, 
p. 152, original emphasis).  
 
Genomics Genetics 
Proteomics 
Converging research fields 
supporting modern drug 
discoveries for cancers 
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Figure 2: Scientific and Technological Patterns in Lung Cancer Treatments  
 
This paper focuses on driving targeted 
therapies for lung cancer, as defined in point 
d) that have generating new anticancer drugs 
that target the tumor protein and its growth. In 
particular, the revolutionary progress in 
molecular biology has shown that cancer cells 
have self-sufficiency of growth signals 
through the accumulation of genetic and 
epigenetic changes. In 1986 Stanley Cohen of 
Vanderbilt University (Nobel Prize in 
Physiology and Medicine) discovers the 
Epidermal Growth Factor (EGF). It acts by 
binding with high affinity to Epidermal 
Growth Factor Receptor (EGF-R) on the cell 
surface and stimulating the intrinsic protein-
tyrosine kinase activity of the receptor. The 
tyrosine kinase activity, in turn, initiates a 
signal transduction cascade that results in a 
variety of biochemical changes within the 
cells that ultimately lead to cell proliferation. 
In addition, these genetic roots of diseases and 
disease progression have induced the 
development of biomarker: “ „A characteristic 
that is objectively measured and evaluated as 
an indicator of normal biological processes, 
pathogenic processes, or pharmacologic 
responses to therapeutic intervention‟ 
(National Institute of Health)”5.  
As genomic changes play a main role in 
cancer growth, mutations of EGF-R occurs in 
                                                                    
5 As quoted by Amir-Aslani and Mangematin, 
2010, p. 204. 
some variety of lung cancer and it can be 
identified by a biomarker, which is important 
for understanding patient differences and 
applying specific treatments with 
effectiveness. In particular, the discovery of 
EGF-R blocking agents Gefitinib and 
Erlotinib has generated two main radical 
innovations that are Iressa® (based on 
Gefitinib) by Astra Zeneca Company(UK-
Sweden) and Tarceva® (blocking agent 
Erlotinib) produced by Roche Group 
(Switzerland)6. These targeted therapies are 
generating a revolution in therapeutic 
treatments of NSCLC since block specific 
enzymes and growth factor receptors involved 
in cancer cell proliferation (Mitsudomi, 2010, 
pp. 101-102): this typology of targeted 
therapy is called signal transduction 
inhibitors(EGF-R tyrosine kinase inhibitors), 
which represent innovative anticancer drugs 
easily administered as one pill per day (also at 
home), whereas the standard platinum-based 
chemotherapy(such as Cisplatin, gemcitabine, 
etc.) is administered intravenously at the 
hospital for treatment of solid malignancies 
(e.g. NSCLC). The scientific advances in the 
grey area of figure 1 are the foundation of the 
modern medicine based on drug discoveries 
that have been moving from mass-oriented 
                                                                    
6 The literature is vast and not fully cited here, but 
a good list of references is found in Dempke et 
al. (2010, pp. 262-263 and pp. 271-274). 
Potentials 
Technological 
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products to target-oriented treatments driven 
by biomarkers that support the effective 
administration of new anticancer drugs to sub-
sets of population. In fact, Paez et al. (2004) 
show that patients with mutated EGF-R 
appeared more likely to respond to Gefitinib 
than those without mutations of the EGF-R. 
Sequist et al. (2007) argue that these 
mutations are associated mainly to patients of 
Asian ethnicity, no-smoking habit and 
histology of adenocarcinoma (that is a 
typology of NSCLC). This group has the best 
response to this targeted therapy as showed by 
several studies (cf. Mitsudomi et al., 2005). In 
particular, Miyagi Cancer Center in Japan 
conducted a phase III trial showing that 
patients with metastatic non-small cell lung 
cancer treated with gefitinib had significantly 
longer progression-free survival in 
comparison with patients who received 
combination of carboplatin plus paclitaxel 
(standard chemotherapy agents): 10.8 months 
vs. 5.4 months7. Gefitinib has also a non-
inferiority vs. mono-chemotherapy agent, such 
as docetaxel. The main effects of Gefitinib in 
the group of patients with EGF-R mutations 
are a tumor regression and a longer 
progression-free survival than traditional 
chemotherapy drugs. In addition, Gefitinib, in 
comparison with traditional chemotherapy 
drugs, has lower toxicity and provides a 
higher quality of life.  
Gefitinib was approved in Japan in the 2002 
for the first time in the world (Mitsudomi, 
2010, p. 102) and is now used in several 
countries for the treatment of adult patients 
with locally advanced or metastatic NSCLC 
with mutations EGF-R (Dempke et al., 2010, 
p. 263).  
Another radical innovation for NSCLC, 
similar to Gefitinib, is based on the blocking 
agent Erlotinib (produced by Roche Group). 
Erlotinib is also a pill that targets the protein 
epidermal growth factor receptor (EGF-R), 
which helps cells to divide. Erlotinib, 
interfering with EGF-R, can stop or regress 
NSCLC growing. In particular, Erlotinib 
inhibits EGF-R signalling by bidding to the 
intracellular tyrosine kinase domain, stopping 
tumor growth. The main effect of Erlotinib is 
                                                                    
7 These results are in the New England Journal of 
Medicine (June 24, 2010). 
to reduce the mortality risk by 19% with an 
increase in median overall survival in the 
overall population from 11 to 12 months (cf. 
Brugger et al., 2009). Clinical trial, over 
2001-2003 period, led by Frances A. 
Shepherd (University of Toronto-Canada) 
showed that the median survival of patients 
who received erlotinib was 6.7 months 
compared to 4.7 months of placebo group. At 
one year, 31 percent of the patients treated 
with erlotinib were still alive vs. 22 percent of 
those taking the placebo8. 
Continuous scientific advances show that 
cancer cells have to attract new blood vessels 
to bring nutrients and oxygen for them to 
growth over a certain size. New compounds 
block the growth of blood vessels to tumors 
(angiogenesis) and as consequence tumor 
growth. In particular, some new anticancer 
drugs target vascular endothelial cell growth 
factor (VEGF) playing a critical role for 
cancer angiogenesis. Inhibition of VEGF is 
the basis for new therapies and effective 
approaches to treat NSCLC and other variety 
of cancers (Reck and Crinò, 2009, p. 2).  
The pathway of radical innovations for 
NSCLC, based on blocking agents Gefitinib 
and Erlotinib, has paving the pattern of  
incremental innovations focused on multi-
targeted blocking agents that target EGF-R, 
human epidermal growth receptor 2 (HER-2) 
and VEGF-R signalling pathways. These 
incremental innovations are due to a learning 
process on the biology of diseases associated 
to the interaction between learning in 
scientific research9 and “learning by doing” 
(Arrow, 1962) in clinical practice. According 
to Dosi (1982, p. 147): “the continuous 
changes are often related to progress along a 
technological trajectory defined by a 
technological paradigm [of the targeted 
therapy in our case study]”. In fact, as NSCLC 
has heterogeneity and complex growth 
patterns by signalling pathway, multi-
inhibition offers fruitful effects to treat 
NSCLC and other variety of cancers. 
Minkovsky and Berezov (2008) show that the 
new blocking agent BIBW-2992 produced by 
                                                                    
8 The results are in The New England Journal of 
Medicine, July 14, 2005. 
9 Morlacchi and Nelson, 2011, p. 513 and p. 521, 
passim; cf .also Kim and Nelson, 2000. 
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Boehringer Ingelheim (Germany) is active 
against lung cancers that are resistant to the 
first-generation of EGF-R inhibitors (that is 
Gefitinib and Erlotinib). Other promising 
compounds for NSCLC by Boehringer 
Ingelheim, in the clinical phase III, are BIBF 
1120 (triple angiokinase inhibitor) and 
Afatinib (Dual irreversible EGF-R and HER2 
inhibitor). These new medical innovations, by 
a continuous learning process (Lenfant, 2003, 
Gershon, 1998), have providing encouraging 
results in NSCLC, increasing the overall 
survival of patients that can triple or 
quadruple in comparison with other 
treatments. It is grated fast-track status for 
some of these anticancer drugs and a first-line 
study vs. Gefitinib/Erlotinib (cf. Dempke et al. 
2010, p. 264; Reck and Crinò, 2009, p. 7).  
Next section describes a methodology to 
measure the rate of scientific and 
technological advances of new anticancer 
drugs, to analyse the evolutionary growth of 
knowledge and underlying factors driving the 
development of these targeted therapies for 
modern clinical practice.  
 
3. STRATEGY OF RESEARCH 
Grupp (2000, p. 143) argues that: 
“innovation literature centres more on 
technical advance and less on scientific 
change”. As a matter of fact, it is important to 
ascertain that scientific advances and changes 
can be considered as an ice-breaker for new 
scientific research fields, creating new 
pathways for future patterns of radical 
technological innovations. 
 In order to investigate the current scientific 
advances of drug discovery in NSCLC that 
will drive future “technological trajectories” 
(Nelson and Winter, 1982), this paper uses the 
database of Scopus (2011) and data mining is 
performed with a series of queries based on 
keywords of new anticancer drugs and 
Boolean operators. 
 
 
 
 
 
 
Data mining is focused on: 
- time horizon 1990 (first year) – 2010 for 
scientific research products (e.g. 
articles); 
- time horizon 1996 (first year) – 2010 for 
patents; 
Aim of the research is to explore the 
patterns of radical innovations for NSCLC, 
compared with standard platinum-based 
chemotherapy alone, such as Cisplatin agent. 
Data on scientific products, which indicate a 
proxy of scientific activities, are retrieved by 
the “Advanced search” window of Scopus 
website, using the “Article title, abstract, 
keyword” tag in the search window. Data on 
patents that indicate a proxy of technological 
activity are retrieved in the SciVerse Scopus 
instrument with a full text query10. 
The vast sample, represented by 140,580 
occurrences of articles and more than 97,000 
occurrences of patents, is the basis to apply 
some models for analyzing the scientific and 
technological pathways of these new 
anticancer drugs. 
As these radical innovations have been 
having an acceleration in their scientific 
activity, a first main aspect is to measure and  
analyse the rate of scientific and technological 
advances by the number of articles and 
patents growth over time.  
 
 
 
                                                                    
10 Technology is based on inventions and 
innovations. Invention is a commercially 
promising product or service, based on new 
science and/or technology that meets the 
requirements for a patent application and/or the 
patent is already granted. On the other hand, 
innovation, which already has a valid and 
granted patent, is the successful entry of a new 
science or technology-based product into a 
particular market. In particular, innovations are 
protected by patents, which indicate the current 
innovation of industries and also commercially 
promising inventions. 
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An exponential model is a fruitful approach to 
measure the dynamics of new anticancer 
drugs based on the following assumptions:  
 
1. aP is the number of articles/patents at 
2000 (1996 for patents) 
2. tP is the number of articles/patents at 
2010 
3. t is the period analyzed  
4.  articles are a proxy of the scientific 
activity, whereas patents are a proxy of 
the technological activity of these research 
fields.  
 
The model is:  
rt
t ePP 0 where e is the base of natural 
logarithm (2.71828…). 
Hence trt e
P
P  
0
 ;   tr
P
P
Log t 
0
; 
.
0
t
P
P
Log
r
t






                     [1] 
r= rate of scientific (or technological) 
advances 
 
This method can offer an analytical 
framework for understanding the evolutionary 
growth of knowledge of these medical 
innovations for lung cancer that have 
generating a revolution in clinical practice. 
However for an in-depth analysis it is 
important to consider that the patterns of the 
scientific activity of specific innovations have 
friction effects over time that can be 
represented by S-shaped functions. An apt 
model to analyse the spatial aspects of 
technological substitution is provided by 
Sahal (1981, pp. 82-89). This spatial model is 
inspired by the analysis performed by 
zoologists concerning the developmental 
biology (cf. Huxley, 1932; Reeve and Huxley, 
1945). 
 
 
 
In particular, the second main aspect of this 
paper is to investigate the relative rate of 
growth of the technological output of some 
new radical innovations for lung cancer in 
comparison with innovative output of 
Cisplatin (applied as standard platinum-based 
chemotherapy).  
A main condition of the model setting is the 
following assumption: 
• The innovative output (Patents) of medical 
innovations has an S-shaped pattern. 
Under this assumption, and the theoretical 
background described, the hypothesis is: 
• Hypothesis. The new targeted therapy for 
lung cancer has been developing, replacing 
current standard platinum-based 
chemotherapy.  
The purpose of the present study is to see 
whether statistical evidence supports this 
hypothesis. The analysis is carried out from 
1996 to 2010 period. 
In particular, let Y(t) be the total number of 
patents at time t of the drug Y’(radical 
innovation)  and X(t) be the total patents at the 
same time of the drug X’ (traditional 
chemotherapy drug).  
Let 1b  and 2b  be the growth rates of total 
outputs Y and X, respectively, such that 
1
2
1 b
b
B  ; if Y and X increase according to an 
S-shaped growth pattern, then 
1
2
1
b
b
B   
measures the relative growth of medical 
innovation X’ in relation to Y’. 
If both Y and X increase according to an S-
shaped growth pattern, one way to represent 
such a pattern formally is in terms of the 
differential equation of logistic function (cf. 
Phillips, 2007).  
For Y(t), the model is (figure 3):  
 tba
K
Y
11
1
exp1 
                     [2] 
 
                                                             Coccia M., Working Paper Cnr-Ceris, N° 01/2012 
 
 12 
 
Figure 3: Diffusion of innovation according to a logistic curve (S-symmetrical) 
 
 
The parameters of the logistic function 
indicate: K1=growth equilibrium level, a1 
=constant depending on the initial conditions 
and b1 = the rate-of-growth parameter, t=time 
Thus, the growth of Y and X is11: 
 
tba
Y
YK
log 11
1 
       [3] 
in a similar way to Y(t), for X(t) the model is: 
 
tba
X
XK
22
2log 
                   [4]
 
 
It can be verified that the logistic curve is a 
symmetrical S-shaped curve with a point of 
inflection at 0.5K  
Solving the equations [3] and [4] for t, the 
result is  
2
1
2
1
1
b
b
XK
X
C
YK
Y









                  [5] 
 
with 
  1211 exp ttbC   since  111 tba    
 
and 
 
                                                                    
11 This part is a re-elaboration of the spatial model 
by Sahal (1981, chap. 5, paragraph 3.2). 1981, 
chap. 5, paragraph 3.2).   
222 tba   
 
Hence Eq. [5] can be reduced to a simple 
model of growth:  
1)(1
B
YAX                       [6] 
where  
 
1
1
2
1
1
2
C
K
K
A
b
b
  
and      
1
2
1
b
b
B   
The logarithmic transformation of the 
equation 1)(1
B
YAX   is a simple linear  
relationship: 
YlogBAlogXlog 11    
so that  
''' 1 XBAY          [7] 
 
1B is the allometry exponent of X in relation 
to Y: 
– If the relative growth of two dimensions 
were isometric, the allometry exponent 
1B  would have a unit value. 
t 
K Saturation or equilibrium 
level 
Y 
 
 K/2 
Point of inflection  
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This hypothesis is expressed as: 
 11 B  
 
– On the other hand, X increases at a 
greater relative rate than Y, the 
hypothesis of positive disproportionate 
(allometric) growth, could be expressed 
as: 
 11 B ; 
– The hypothesis that X has negative 
disproportionate (allometric) growth in 
relation to Y could be expressed as: 
 11 B   
 
The model [7] measures the magnitude of 
relative growth in a simpler way than a wide 
variety of econometric approaches. Sahal 
(1981, Chp. 5) has applied this model to 
analyse the technological substitution of 
different innovations. 
 
Mutatis mutandis, our model is given by: 
1)(
B
tt xay          [8] 
where:  
a is a constant 
yt is the number of patents of the new 
anticancer drug, that is Gefitinib, at time t; 
xt is the number of patents of the Cisplatin-
based therapy that is a reference treatment for 
advanced NSCLC.  
The relevance of this spatial model of 
technological substitution is that it provides 
simple and fruitful results to analyse the 
patterns of this medical innovation. In 
particular, the scientific progress of 
innovations is generally analyzed by an 
allometric process of growth (“this term … 
denote[s] disproportionate change in the size 
of an organ as a consequence of change in the 
overall size of a biological system” - Sahal, 
1981, p. 97, footnote 6). That is, substitution 
of one innovative output for the other 
generally involves disproportionate growth of 
one in relation to the other. 
The empirical evidence of technological 
substitution analyzed by the logarithmic 
transformation of the model [8] provides main  
 
findings in simple way since contains only 
two parameters, estimated by ordinary least 
squares. This model is quite robust and its 
form remains invariant under a variety of 
different starting point.  
4. RESULTS 
The main R&D process of NSCLC is 
focused on the last 15 years. This research 
uses data of the scientific production (articles 
and patents) of these vital innovations, 
because as it is well known, scientific 
pathways anticipate (drug) discoveries, 
opening technological trajectories that will be 
diffused in not-too-distant future for the 
wellbeing of societies.  
The main findings of this paper are: 
• Rates of scientific and technological 
advances 
The rates of growth measured by articles 
and patents provide main information about 
the current scientific and technological 
advances. Table 2 shows that Gefitinib has 
higher rate of scientific growth based on 
articles of journals, whereas Erlotinib has high 
rates both of scientific and technological 
advances. 
Table 2 shows, ceteris paribus, the rates of 
scientific and technological advances of new 
and traditional anticancer drugs for NSCLC, 
measured by model [1] applied on the overall 
period.  
It is important to note that technological 
advances depend on the accumulation of 
knowledge and the dynamic pathway for lung 
cancer treatments has spurring new 
trajectories of anticancer drugs based on 
blocking agent BIBW-2992, Afatinib and 
BIBF 1120, which are incremental 
innovations in comparison with Gefitinib and 
Erlotinib: e.g. the rate of scientific production 
of the new anticancer drug “Afatinib” is 
76.75%, whereas BIBW-2992 has a rate of 
technological advances equal to 77.42%, 
showing as these incremental innovations 
have an growing scientific and technological 
accumulation of knowledge. 
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Table 2: Rates of growth of drugs for lung cancer  
   Treatment for Lung Cancer 
% Rate of  
scientific advances 
(measured by article) 
2000-2010 period 
% Rate of  
technological advances  
(measured by patents) 
1996-2010 period 
New drugs based on targeted therapy 
  Gefitinib 46.76 18.77 
Erlotinib 45.76 47.05 
Afatinib (2009-2010)* 76.75 -- 
  BIBW-2992( 2006-2010)* 
 
48.67 77.42 
  BIBF 1120 (2004-2010)* 
 
56.99 20.50 
Standard chemotherapy agents 
  Cisplatin 4.93 15.36 
Gemcitabine (used in combination with the Cisplatin)  15.19 40.20 
Docetaxel 32.00 30.09 
Paclitaxel 21.44 25.34 
 
NOTE: Gefitinib has a total number of occurrences equal to 9981 (articles) and 6875 (patents); Erlotinib 
has 8105 occurrences of articles and 5281 of patents. Afatinib has 33 occurrences of articles. BIBW-2992 
has 147 occurrences of articles and 103 of patents. BIBF 1120 has 123 occurrences of articles and 156 of 
patents. Standard chemotherapy agents have higher number of occurrences: Cisplatin 55,390 (articles) and 
44,971 (patents), Gemcitabine has 18,441 occurrences of articles and 17,092 of patents, Docetaxel 18,739 
(articles) and 18,421 (patents), Paclitaxel 38,236 (articles) and 36,882 (patents). * New compounds that are 
in the clinical phase III.  
 
Specifically, these new compounds that are 
in the clinical phase III confirm that a great 
deal of scientific and technological progress is 
underpinned by gradual refinement of certain 
basic patterns. In other words, according to 
Sahal (1981, p. 112): “the evolution of 
technology  . . . . is governed by a process of  
cumulative change”.  
In addition, as trends of these new 
anticancer drugs have S-patterns (Figure 1A 
and 2A in Appendix), in order to in-depth 
analyse their dynamics, it is important to 
divide the rate of growth in temporal phases. 
Table 3 displays the rate of 
scientific/technological advances per main 
phases of S-pattern. 
Table 3 shows as the scientific advances of 
Gefitinib are started before of Erlotinib and 
now, Gefitinib is in a maturity phase of 
evolutionary growth of knowledge for articles 
and for patents. As far as Afatinib (ibidem 
BIBF 1120 and BIBW-2992) is concerned, 
this incremental innovation is at the early 
stage of growth and higher rates of scientific/ 
technological advances indicate that future 
innovative pathways to treat NSCLC may be 
led by these new anticancer drugs, although 
some of them do not have and/or have low 
patenting activities. 
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Table 3: Rates of growth of new drugs for lung cancer based on phases 
 of the S-shaped pattern 
  Radical innovations 
Incremental 
innovation 
Period Phases Articles Gefitinib  % 
Erlotinib  
% 
Afatinib % * 
(2009-2011) 
1997-2002 Growth 93.02 67.17 76.75 
2002-2006 Transition 29.39 43.67 -- 
2006-2010 Maturity 1.03 10.16 -- 
Period Phases Patents    
1997-2002 Growth 42.14 83.63 -- 
2002-2006 Transition 20.18 1.73 -- 
2006-2010 Maturity 11.68 -- -- 
 
Note: * New compound that is in the clinical phase III.  
 
 
Table 4: Summary of log-linear model 
R R Square Adjusted R Square 
Std. Error of 
the Estimate 
0.93 0.86 0.85 0.47 
The independent variable is LN CISPLATIN (Patents). Data: 1996-2010. 
 
 
 
Table 5: ANOVA 
 Sum of Squares df Mean Square F Sig. 
Regression 17.09 1 17.09 78.46 0.00 
Residual 2.83 13 0.22   
Total 19.92 14    
The independent variable is LN CISPLATIN (Patents). Data: 1996-2010. 
 
 
 
 
Table 6: Coefficients of log-linear model 
 
Unstandardize
d Coefficients 
 
t Sig. 
 
B Std. Error 
  LN CISPLATIN (Patents)  1.34 0.15 8.86 0.000 
(Constant) -4.83 1.18 -4.09 0.001 
The dependent variable is LN Gefitinib (Patents). Data: 1996-2010.  
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It is also important to ascertain that firms in 
drug discovery sector could prefer to keep 
new compounds secret rather than patents 
them12, in order to avoid imitation processes 
in current competitive markets (cf. Ottoz and 
Cugno, 2009)13.  
• Technological substitution and rate of 
relative growth  
As the patterns of radical innovations and 
standard chemotherapy drugs for NSCLC are 
S-Shaped (Figs. 1A-2A-3A), it is possible to 
apply the model of technological substitution 
by Sahal (1981). The absolute production of 
patents of the new anticancer drugs relative to 
the production of patents of the traditional 
chemotherapy agent, plotted on double-
logarithmic scale, show a linear trend (figure 
4A).  
Now it is essentially to measure the growth 
of the production of one (new) anticancer 
drug relative to the other (standard platinum-
based chemotherapy alone). The coefficient of 
the independent variable in the model [7] of 
the spatial process of technological 
substitution provides this magnitude. The 
results for the new anticancer drug Gefitinib 
are presented in the tables (4-6), whereas for 
the anticancer drug Erlotinib, as the patenting 
activity begun later (i. e. since 2003), the 
estimates do not provide significant results 
because of the shorter period of data.  
The first thing to be said about these results 
is that the model explains 85% variance in the 
data (Tab. 4). In addition the parametric 
                                                                    
12 I am grateful to Vittorio Valli for this 
observation.  
13 Friedman, Landes and Posner (1981) claim that: 
“ „ Inventors choose trade secret protection when 
they believe patent protection . . . will give them 
a reward substantially less than the benefit of 
their invention‟ ” (as quoted by Ottoz and 
Cugno, 2009, p. 2).  
estimates of the model are unbiased and the 
significance of coefficients and the 
explanatory power of the equations are good 
(tab. 5 and 6).  
The coefficient of the model [7] is equal to 
unity if the rates of production of the two 
anticancer drugs are equal. The result of table 
6 indicates that the value of the relative 
growth rate is significantly differ from unity: 
that is, the rate of growth of the technological 
output of the radical innovation (Gefitinib) 
relative to standard platinum-based 
chemotherapy alone based on Cisplatin, is 
1.34. This finding supports the hypothesis: 
radical innovation (Gefitinib) to treat NSCLC 
has generally an allometric process of growth; 
that is, substitution of the innovative output 
for the other generally involves 
disproportionate growth of one (new 
anticancer drug, Gefitinib) in relation to the 
other (standard platinum-based chemotherapy 
alone, i.e. Cisplatin).  
5. DISCUSSION 
Lung cancer is a main cause of death 
worldwide and some chemotherapy agents 
have reached the maturity phase in the 
treatment of advanced non-small cell lung 
cancer (NSCLC). This paper shows as new 
anticancer drugs are driven by the insurgence 
of the technological paradigm of targeted 
therapy originated by scientific convergence 
of genetics, genomics and proteomics (fig.1). 
Targeted cancer therapies, by focusing on 
molecular and cellular changes that are 
specific to cancer, are more effective than 
other types of treatments, including 
chemotherapy and radiotherapy, and less 
harmful to normal cells (cf. National Cancer 
Institute, 2011). 
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Table 7: Different factors of technological substitution of new drugs for lung cancer 
Determinants of boost Factors of friction 
- Faster tumor regression 
- Lower adverse drug reaction 
- Longer overall survival of patients 
- Better living 
- Administer at home 
- Higher quality of life 
 
- Time consuming iter to use new 
anticancer drugs (histological 
analysis, biomarker, etc.) 
- Lack of labs and/or technological 
knowledge and/or human capita, 
and/or equipment in hospitals for 
EGF-R mutation  
- High-cost drugs  in comparison to 
traditional chemotherapy agents 
- Decision of oncologists affects by 
budgetary constraints of public 
health sector 
 
 
Converging research fields (grey area in 
figure 1) have improving the scientific 
understanding of diseases and underpinning 
these revolutionary innovations to treat 
NSCLC, which lead to longer and better 
living of patients. The targeted therapy for 
NSCLC is a vital case study since its scientific 
advances are similar to other new drugs that 
fight different cancers, such as lymphoma, 
leukaemia, as well as Alzheimer‟s and 
Parkinson diseases, human immunodeficiency 
and hepatitis C viruses. 
Although these new medical innovations 
have lower toxicity, prolong survival and 
improve the quality of life of patients, their 
patterns of diffusion have friction effects due 
to high cost for healthcare. The main drivers 
and friction factors for the technological 
substitution of new anticancer drugs vs. 
standard chemotherapy agents are synthesized 
in the table 7. 
The converging research fields in figure 1 
are also driving a strategic change of 
corporate R&D Drug discovery process, 
which is based on translational medicine: “the 
interplay between basic laboratory science 
and exploratory clinical research. It 
encompasses preclinical investigations of the 
biological effects of therapeutics as well as 
clinical investigations aimed at enhanced 
understanding of disease biology” (as defined 
by Roche, 2011). as a matter of fact, the 
“technological guideposts” (Sahal, 1981, pp. 
32-36), based on innovative drug design 
technology and experimental approaches, is 
driving an industrial and corporate change, 
which is due to rational modes of drug 
discovery that develop integrative capabilities 
fundamental to support drug discovery 
process of firms (cf. Henderson, 1994, p. 
607ff). Morlacchi and Nelson (2011, p. 513) 
claims that: “as the therapy evolves, the 
principal actors involved in advancing the 
therapy tend to change as well”. In addition, 
R&D costs for drug discovery are increasing 
exponentially (at a pace of 10.8% per annum, 
whereas revenue from new drugs is growing 
at the rate of 7% -Jain, 2000, p. 320), with a 
development process of new drugs (over the 
past decade) of about 11-15 years (Biofocus, 
2011) and less than 10% of drugs deliver 
acceptable commercial returns (Afshar, 2003, 
p. 392). In order to cope with these main 
tendencies in drug discovery industry, table 8 
shows the current structure for R&D, research 
areas and corporate strategy of three leading 
companies that have driving innovation 
pathways to treat lung cancer and other 
typologies of cancers and diseases.  
In general, leading companies, in order to 
improve the organizational behaviour for drug 
discovery (that have blockbusters status or 
potential) in fast-changing scenarios, have a 
current strategic change focused on:  
 
a) high intensity of R&D focused on critical 
topics in order to reduce the cost of drug 
development;  
b) reduction of the time to market to 4 years 
(Jain, 2000, p. 318); 
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c) strategic partnership with public and 
private labs as well as  strategic alliances 
mainly with biotechnology and 
nanotechnology firms, in order to spur drug 
discovery process. In particular, the current 
scientific and technological advances of new 
drugs are also boosted by a vital learning 
process that is discussed in the next section.  
• Learning process underlying technological 
change in clinical practice 
The pace of innovation dynamics is based 
on continuous small scientific advances, 
rather than drastic breakthroughs, both in  
diagnosis and therapy settings. The scientific 
and technological advances of drug discovery 
take place in stages (assay development, lead 
optimization, pre-development, preclinical 
development, clinical research) and there are 
significant time lags between the acquisition 
of information in clinical research and the 
development/improvement of new anticancer 
drugs. The steps of R&D are interwoven and 
blockbusters are best pursued by a learning 
process in cooperation with end users 
(patients). In particular, this gradual R&D 
process that drives new therapies is affected 
by the progress of “Learning in practice” and 
“Advances in biomedical scientific 
understanding” (Morlacchi and Nelson, 2011, 
p. 512, passim). In fact, it is important to note 
that the radical innovations of modern 
medicine generally depend on learning 
processes driven by the acquisition of skills 
through the clinical research based on 
participation of patients and medical staff. 
This is the so-called “ „learning via diffusion‟ 
…. The increased adoption of a technology 
paves the way for improvement in its 
characteristics” (Sahal, 1981, p. 114). Another 
essential aspect driving the targeted therapy is 
the collective and cumulative learning that 
supports the evolution of technological 
trajectories for new anticancer drugs (cf. also 
Morlacchi and Nelson, 2011, pp. 521-523). 
However, it is important to ascertain that in 
specific medical fields, the technological/ 
scientific learning is context dependent14. For 
instance, the role of learning in driving 
innovations for lung cancer is different from 
learning for failing hearts: a key role to treat 
failing hearts is played by developing 
effective medical technology (new 
implantable device for hearth) whereas for 
lung cancer, new anticancer drugs are driven 
mainly by a learning process based on 
scientific advances in genetics and genomics, 
associated to learning in clinical practice. 
Therefore innovations and learning process to 
treat several diseases tends to be of different 
nature: “the resulting know-how is often 
fragmentary and context dependent” (Sahal, 
1981, p. 198). As a matter of fact, the 
advancements in scientific knowledge have a 
general diffusion in all clinical practice, 
whereas the development of new drugs is 
localized in specific diseases (e.g. new 
anticancer drugs are effective for NSCLC and 
not for small cell lung cancer)15. This learning 
process driving technological advancements 
in medicine is also systematically related to 
certain peculiarities present in managerial and 
organizational behaviour of firms: the three 
leading companies in lung cancer treatments 
have high level of cumulated investment in 
R&D as essential determinant of their 
innovation processes as well as corporate 
strategies focused on selected acquisitions and 
alliances both in pre-clinical discovery and in 
clinical development phases of research. In 
fact, one of the most critical variable in long-
run technological development of drug 
discovery for lung cancer is learning by 
clinical research and externally strategic 
alliances and partnerships, which depend on 
total investment of company (not only R&D 
investments).   
                                                                    
14 The discussion of some parts of this sections has 
as conceptual background the theory of Sahal 
(1981, chaps 6 and 9).  
15 Allen et al. (1979, p. 695) argue: “Science may 
be said universal. . . . Technology, on the other 
hand, is not universal”.  
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Table 8: R&D Structure and corporate strategy of three leading company for medical 
innovative treatments 
AstraZeneca 
In 1999 fusion between Swedish Astra 
AB and English Zeneca Group. 
Roche (Switzerland) Boehringer Ingelheim GmbH (Germany) 
AstraZeneca currently employs 10,000 
personnel in research and development, 
spends US$3.5 billion on R&D annually. 
In 2010, Roche had over 80,000 employees 
worldwide and invested over US$10.6 billion in 
R&D. The Group posted sales of 56.9 billion U$.  
Boehringer Ingelheim has more than 
7,000 highly qualified people working in 
R&D out of 42,224 Boehringer 
Ingelheim employees worldwide. In 
2010, Boehringer Ingelheim posted net 
sales of 17.8 billion U$ while investing 
almost 24 percent of net sales (about 3.5 
billion euro) in the largest business 
segment Prescription Medicines on 
R&D.  
R&D Areas of Interest 
Oncology (apoptosis, cell cycle control, 
proliferation/angiogenesis, immune 
stimulation, motility /invasion, 
chemoprevention) 
• Cardiovascular/Metabolism 
• Central Nervous System 
• Gastrointestinal 
• Respiratory/Inflammation 
• Pain Control 
• Infection 
• Oncology  
• Virology  
• Inflammation  
• Metabolism  
• Central Nervous System 
 Respiratory diseases 
 Cardio metabolic diseases 
 Neurological diseases  
 Immunology  
 Infectious diseases  
 Oncology 
Boehringer Ingelheim's Research & 
Development focus on angiogenesis 
inhibition, signal transduction and cell-
cycle kinase inhibition. R&D in 
oncology is committed to discover 
improved medicines against cancers as: 
lymphoma, solid tumors, and leukaemia. 
Corporate change for driving future drug discovery 
Acquisition of biotechnology firms, 
partnership with public and private R&D 
labs worldwide.  
It has seeking external alliances in both 
the pre-clinical discovery and the clinical 
development phases of research.  
The disciplines of genetics and genomics have 
become central pillars of Roche's research. 
Roche is also the world leader in in-vitro 
diagnostics, tissue-based cancer diagnostics and 
a pioneer in diabetes management. Genentech, 
United States, is a wholly owned member of the 
Roche Group. Academy-industry partnership 
seeks to propel progress in translational 
medicine and personalized healthcare. Roche and 
university of Basel are entering a strategic 
alliance to establish and manage Translational 
Medicine Research Hub (i.e. to advance 
understanding of the cellular mechanisms that 
form the basis of disease and its treatment by 
bringing together medically oriented basic 
science and clinical research capabilities).  
R&D has been transformed thanks to 
ground breaking new technology, such as 
high-throughput and ultra-high-
throughput screening. The acquisition of 
the injectables manufacturer has given 
the hospital segment a major boost. New 
marketing alliances have been formed 
with leading companies, such as 
Genentech, Abbott Laboratories, Glaxo 
Wellcome, Pfizer and Eli Lilly. 
Acquisition of the micro-technology 
company STEAG microParts GmbH 
from STEAG AG, Essen. Strategy for 
the next 10 years foresees Boehringer 
Ingelheim continuing to research and 
develop medicines supported by in 
licensing and selected acquisitions and 
alliances. 
Source: Extract by: http://www.astrazeneca.ca/en/research/ 
                                http://www.rochecanada.com/portal/ca/research_development2 
                                http://www.boehringer-ingelheim.com/research_development.html (accessed 29 June 2011) 
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6. CONCLUDING REMARKS 
This study has shed light on current patterns 
of radical innovations for lung cancer, driven 
by converging genetics, genomics and 
proteomics that has generating a revolution in 
clinical practice, increasing the survival and 
quality of life of patients. In particular, this 
paper shows the allometric growth of 
scientific knowledge in new anticancer drugs. 
The interesting technological pattern of these 
new targeted therapies has a common origin 
to several new drugs and an evolution that can 
be generalized to understand the nature and 
barriers of the technological change that has 
driving the modern medicine.  
The current adoption of these new 
anticancer drugs is determined by the 
superiority “relative advantage” (Rogers, 
1995) over its predecessor (mainly 
chemotherapy agents), in terms of lower 
toxicity and higher survival of patients; 
however there are also some barriers over 
their process of adoption (table 7) based on 
budgetary constraints of hospitals and 
restrictive health policy by countries in 
current turbulent economic scenarios that 
seem inhibit the vast diffusion of these main 
radical innovations in clinical practice (the 
new anticancer drugs have roughly a double 
price in comparison with standard platinum-
based chemotherapy).  
As a matter of the fact, these new treatments 
for NSCLC seem that increase costs for health 
sector at local level, but a global analysis may 
show reductions of cost in the long run, in 
comparison to tradition chemotherapy drugs 
(because of reduction in day-hospital costs, 
reduction of costs to cure adverse drug 
reactions of traditional chemotherapy agents, 
etc.). Chouaid et al. (2007, p. 1509), 
analyzing the economic impact of Gefitinib, 
show that: “the price of Gefitinib had little 
influence on the total cost . . . the cost of 
third-line Gefitinib therapy for NSCLC 
appears acceptable from healthcare payer‟s 
perspective” (p. 1509). However, health 
policy of several countries is focused on 
short-term cost control behaviour and does not 
encourage long term disease management and 
cost saving strategies. In fact, socio-economic 
studies focused on new drugs for Alzheimer‟s 
disease, with economic effects similar to new 
anticancer drugs for NSCLC, indicate a net 
saving of these new drugs in comparison with 
traditional medicine over a period of 2-5 years 
(Hauber et al., 2000, p. 65).  
Healthcare should have a non-myopic -or 
far-seeing- health policy (i.e. consider the 
lung-run systemic costs of the overall health 
sector for cancer treatments rather than short-
run comparisons based mainly on specific cost 
of new and old chemotherapy agents) in order 
to pave the pathway to spread of these 
targeted therapies that have generating a 
revolution to treat and we hope to cure the 
lung cancer in a not-too distant future. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Coccia M., Working Paper Cnr-Ceris, N° 01/2012                                                              
 
 21 
SUMMARY OF THE RESEARCH 
 
PURPOSE: The purpose of this paper is to analyse the patterns of vital radical innovations to 
treat lung cancer that have generating a revolution in clinical practice.  
METHODS. Exponential and spatial model of technological substitution are applied on 
140,580 occurrences of articles and more than 97,000 occurrences of patents to determine the 
patterns of innovative targeted therapies.  
RESULTS. The scientific pattern of growth of new anticancer drugs is an allometric process 
that involves a disproportionate growth in relation to standard platinum-based chemotherapy 
alone, driven by a high rate of scientific and technological advances as well as learning 
process in clinical practice.  
CONCLUSION: Lung cancer is a main cause of death worldwide and traditional 
chemotherapy has reached the maturity phase in the treatment of advanced non-small cell lung 
cancer. This study has shed light on evolutionary growth of knowledge of radical innovations 
for lung cancer, driven by converging molecularly, genetically and clinically advances, that 
have been generating innovative treatments with therapeutic benefits in terms of overall 
survival of patients. A vital role is played by learning process underlying the technological and 
organizational change in clinical practice. These technological trajectories, spread from the 
technological paradigm of the targeted therapy, might drive future oncology to cure the variety 
of cancers in not-too-distant future. 
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APPENDIX A: S-SHAPED PATTERNSAND TREND 
 OF ANTICANCER DRUGS 
 
Figure 1A: Patterns of articles of two medical innovations for lung cancer over time 
(typical pattern S-shaped). Note: BIBF 1120 and BIBW 2992 have similar patterns 
 
 
 
Note: BIBF 1120 and BIBW 2992 have similar patterns 
Figure 2A: Patterns of patents of two medical innovations for lung cancer over time 
(typical pattern S-shaped) 
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Note: Gemcitabine has similar patterns 
Figure 3A:Pattern of articles/patents of the standard platinum-based chemotherapy 
“Cisplatin” for lung cancer (typical pattern S-shaped over time). 
 
Figure 4A: Linear trend of data of new and standard anticancer agents for lung plotted on 
double-logarithmic scale over 1996-2010 period 
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